cvl-231
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2019 (NCT04136873)
Timeline
Indications
Mechanism of action
- Unspecified targetACTIVATOR
activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933187 | Phase 1 | Jul 19, 2023 | Cerevel Therapeutics, LLC |
| NCT05443724 | Phase 2 | Sep 2, 2022 | Cerevel Therapeutics, LLC |
| NCT05227690 | Phase 2 | Jun 30, 2022 | Cerevel Therapeutics, LLC |
| NCT05227703 | Phase 2 | Jun 30, 2022 | Cerevel Therapeutics, LLC |
| NCT05245539 | Phase 1 | Jan 24, 2022 | Cerevel Therapeutics, LLC |
| NCT05106309 | Phase 1 | Nov 22, 2021 | Cerevel Therapeutics, LLC |
| NCT04787302 | Phase 1 | Jun 1, 2021 | Cerevel Therapeutics, LLC |
| NCT04136873 | Phase 1 | Oct 15, 2019 | Cerevel Therapeutics, LLC |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerevel Therapeutics, LLC | For profit | 8 | 8 | 2 | 2019 |
1 organizations
Page 1 / 1